Biophytis SA ((NasdaqCM:BPTS, PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes
As of December 31, 2022, the Company had $154 million of liquidity, comprised of cash, cash equivalents and short term investments, and no debt. The Company anticipates it has sufficient liquidity to achieve initial
Honest Co (NASDAQ:HNST) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.05) by 180 percent. This is a 40 percent decrease over losses of $(0.10) per share from the same